Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Silo Pharma (SILO) EBITDA (2019 - 2025)

Silo Pharma's EBITDA history spans 7 years, with the latest figure at -$1.1 million for Q3 2025.

  • For Q3 2025, EBITDA fell 20.89% year-over-year to -$1.1 million; the TTM value through Sep 2025 reached -$5.1 million, down 35.14%, while the annual FY2024 figure was -$4.4 million, 18.27% down from the prior year.
  • EBITDA for Q3 2025 was -$1.1 million at Silo Pharma, up from -$1.2 million in the prior quarter.
  • Across five years, EBITDA topped out at -$436849.0 in Q2 2021 and bottomed at -$1.7 million in Q4 2024.
  • The 5-year median for EBITDA is -$942416.0 (2021), against an average of -$951646.3.
  • The largest YoY upside for EBITDA was 56.17% in 2021 against a maximum downside of 465.48% in 2021.
  • A 5-year view of EBITDA shows it stood at -$942416.0 in 2021, then tumbled by 76.44% to -$1.7 million in 2022, then skyrocketed by 32.24% to -$1.1 million in 2023, then tumbled by 55.15% to -$1.7 million in 2024, then surged by 36.58% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for SILO's EBITDA are -$1.1 million (Q3 2025), -$1.2 million (Q2 2025), and -$1.0 million (Q1 2025).